Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 28Small Cell Lung Carcinoma 24Fallopian Tube Neoplasms 12Uterine Cervical Neoplasms 8Carcinoma, Ovarian Epithelial 8Neuroblastoma 7Lung Neoplasms 6Sarcoma 3Neoplasms 3Retinoblastoma 2Neoplasm Metastasis 2Malignant mesenchymal tumor 2Ganglioneuroblastoma 2Carcinoma, Non-Small-Cell Lung 2Solid Tumors 1SCLC 1Rhabdomyosarcoma 1Retinal Neoplasms 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Pleuropulmonary blastoma 1Peritoneal Neoplasms 1Neuroectodermal Tumors, Primitive, Peripheral 1Localized Extraskeletal Ewing Sarcoma 1Leukemia 1Eye Neoplasms 1Extensive Stage Small Cell Lung Cancer (ES-SCLC) 1Endometrial Neoplasms 1Carcinoma 1

Interventions

Watchful Waiting 1Vincristine 1Topotecan 1Specimen Handling 1Razoxane 1Observation 1Magnetic Resonance Spectroscopy 1Ifosfamide 1High-Energy Shock Waves 1Doxorubicin 1Dexrazoxane 1Dactinomycin 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Pleuropulmonary blastoma × Topotecan × Clear all
NCT06647953 2026-05-05

Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma

Children's Oncology Group

Phase 3 Recruiting
110 enrolled

Pleuropulmonary blastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡